Literature DB >> 9487556

A 31P CP/MAS NMR study on dehydration of disodium clodronate tetrahydrate.

J T Timonen1, E Pohjala, H Nikander, T T Pakkanen.   

Abstract

PURPOSE: 31P CP/MAS NMR is used to characterize stability and changes in solid state properties of disodium clodronate tetrahydrate upon variable temperature and slow dehydration.
METHODS: Variable temperature 31P CP/MAS NMR spectroscopy.
RESULTS: A fast rise in temperature leads to loss of lattice waters and produces an averaged structure characterized by a single 31P NMR resonance at 398 K. Slow room temperature dehydration converts the crystalline form to an anhydrous structure with two non-equivalent phosphorus atoms. The molecular skeleton of clodronate is stable within the temperature range 296 K-398 K of experiments. Rehydration of the anhydrous samples at room temperature restores the crystalline tetrahydrate form verified by a 31P CP/MAS NMR spectrum similar to that of a virginal sample.
CONCLUSIONS: Solid state NMR is a method which can offer both molecular and crystal scale information, when either bulk or dosage forms of a drug can be altered by temperature or by loss of lattice waters or solvents. The experiments are easy to perform, though time consuming, especially when low abundant nuclei are examined.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9487556     DOI: 10.1023/a:1011965107205

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  3 in total

1.  Relationship between Solid State NMR Parameters and X-ray Structural Data in Tricadmium Phosphates.

Authors:  S. Aime; G. Digilio; R. Gobetto; A. Bigi; A. Ripamonti; N. Roveri; M. Gazzano
Journal:  Inorg Chem       Date:  1996-01-03       Impact factor: 5.165

2.  Determination of the composition of delavirdine mesylate polymorph and pseudopolymorph mixtures using 13C CP/MAS NMR.

Authors:  P Gao
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

Review 3.  Pharmaceutical solids: a strategic approach to regulatory considerations.

Authors:  S Byrn; R Pfeiffer; M Ganey; C Hoiberg; G Poochikian
Journal:  Pharm Res       Date:  1995-07       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.